Color vision disturbances secondary to oral tranexamic acid

Abstract Tranexamic acid (TXA) is an antifibrinolytic commonly used to reduce blood loss due to surgical procedures, heavy menstruation, trauma, bleeding disorders, among other uses. Possible adverse reactions associated with TXA include abdominal pain, headache, fatigue, cerebral thrombosis, dizzin...

Full description

Bibliographic Details
Main Authors: Adam S. Kiser, Gena L. Cooper, Jonathan D. Napier, Gavin T. Howington
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Journal of the American College of Emergency Physicians Open
Subjects:
Online Access:https://doi.org/10.1002/emp2.12456
id doaj-7749a03b93f84b71bd3094e6b024d797
record_format Article
spelling doaj-7749a03b93f84b71bd3094e6b024d7972021-06-29T14:38:33ZengWileyJournal of the American College of Emergency Physicians Open2688-11522021-06-0123n/an/a10.1002/emp2.12456Color vision disturbances secondary to oral tranexamic acidAdam S. Kiser0Gena L. Cooper1Jonathan D. Napier2Gavin T. Howington3University of Kentucky College of Pharmacy Lexington Kentucky USADepartment of Emergency Medicine University of Kentucky HealthCare Lexington Kentucky USADepartment of Emergency Medicine University of Kentucky HealthCare Lexington Kentucky USADepartment of Pharmacy Practice and Science University of Kentucky College of Pharmacy Lexington Kentucky USAAbstract Tranexamic acid (TXA) is an antifibrinolytic commonly used to reduce blood loss due to surgical procedures, heavy menstruation, trauma, bleeding disorders, among other uses. Possible adverse reactions associated with TXA include abdominal pain, headache, fatigue, cerebral thrombosis, dizziness, retinal artery occlusion, chromatopsia, and more. We present a case of acute color vision disturbance developed soon after initiation of oral TXA for epistaxis prophylaxis in the setting of factor VII deficiency. To our knowledge we report the only case of color vision disturbance in a pediatric patient and the only case after receiving oral TXA. Soon after discontinuing oral TXA the patient's altered perception of color vision resolved. The patient was subsequently discharged home with a prescription for an alternative antifibrinolytic (aminocaproic acid) and follow‐up with neuro‐ophthalmology.https://doi.org/10.1002/emp2.12456antifibrinolyticfactor VII deficiencyocular pathologypediatrictranexamic acid
collection DOAJ
language English
format Article
sources DOAJ
author Adam S. Kiser
Gena L. Cooper
Jonathan D. Napier
Gavin T. Howington
spellingShingle Adam S. Kiser
Gena L. Cooper
Jonathan D. Napier
Gavin T. Howington
Color vision disturbances secondary to oral tranexamic acid
Journal of the American College of Emergency Physicians Open
antifibrinolytic
factor VII deficiency
ocular pathology
pediatric
tranexamic acid
author_facet Adam S. Kiser
Gena L. Cooper
Jonathan D. Napier
Gavin T. Howington
author_sort Adam S. Kiser
title Color vision disturbances secondary to oral tranexamic acid
title_short Color vision disturbances secondary to oral tranexamic acid
title_full Color vision disturbances secondary to oral tranexamic acid
title_fullStr Color vision disturbances secondary to oral tranexamic acid
title_full_unstemmed Color vision disturbances secondary to oral tranexamic acid
title_sort color vision disturbances secondary to oral tranexamic acid
publisher Wiley
series Journal of the American College of Emergency Physicians Open
issn 2688-1152
publishDate 2021-06-01
description Abstract Tranexamic acid (TXA) is an antifibrinolytic commonly used to reduce blood loss due to surgical procedures, heavy menstruation, trauma, bleeding disorders, among other uses. Possible adverse reactions associated with TXA include abdominal pain, headache, fatigue, cerebral thrombosis, dizziness, retinal artery occlusion, chromatopsia, and more. We present a case of acute color vision disturbance developed soon after initiation of oral TXA for epistaxis prophylaxis in the setting of factor VII deficiency. To our knowledge we report the only case of color vision disturbance in a pediatric patient and the only case after receiving oral TXA. Soon after discontinuing oral TXA the patient's altered perception of color vision resolved. The patient was subsequently discharged home with a prescription for an alternative antifibrinolytic (aminocaproic acid) and follow‐up with neuro‐ophthalmology.
topic antifibrinolytic
factor VII deficiency
ocular pathology
pediatric
tranexamic acid
url https://doi.org/10.1002/emp2.12456
work_keys_str_mv AT adamskiser colorvisiondisturbancessecondarytooraltranexamicacid
AT genalcooper colorvisiondisturbancessecondarytooraltranexamicacid
AT jonathandnapier colorvisiondisturbancessecondarytooraltranexamicacid
AT gavinthowington colorvisiondisturbancessecondarytooraltranexamicacid
_version_ 1721354726640975872